These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 31886717)

  • 1. Activin type II receptor ligand signaling inhibition after experimental ischemic heart failure attenuates cardiac remodeling and prevents fibrosis.
    Castillero E; Akashi H; Najjar M; Ji R; Brandstetter LM; Wang C; Liao X; Zhang X; Sperry A; Gailes M; Guaman K; Recht A; Schlosberg I; Sweeney HL; Ali ZA; Homma S; Colombo PC; Ferrari G; Schulze PC; George I
    Am J Physiol Heart Circ Physiol; 2020 Feb; 318(2):H378-H390. PubMed ID: 31886717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activin type II receptor signaling in cardiac aging and heart failure.
    Roh JD; Hobson R; Chaudhari V; Quintero P; Yeri A; Benson M; Xiao C; Zlotoff D; Bezzerides V; Houstis N; Platt C; Damilano F; Lindman BR; Elmariah S; Biersmith M; Lee SJ; Seidman CE; Seidman JG; Gerszten RE; Lach-Trifilieff E; Glass DJ; Rosenzweig A
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p38 mitogen-activated protein kinase inhibition decreases TNFalpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia.
    Yin H; Zhang J; Lin H; Wang R; Qiao Y; Wang B; Liu F
    Inflammation; 2008 Apr; 31(2):65-73. PubMed ID: 17943427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.
    See F; Thomas W; Way K; Tzanidis A; Kompa A; Lewis D; Itescu S; Krum H
    J Am Coll Cardiol; 2004 Oct; 44(8):1679-89. PubMed ID: 15489104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction.
    Tan SM; Zhang Y; Connelly KA; Gilbert RE; Kelly DJ
    Am J Physiol Heart Circ Physiol; 2010 May; 298(5):H1415-25. PubMed ID: 20154262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of TGF-beta1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats.
    Matsumoto-Ida M; Takimoto Y; Aoyama T; Akao M; Takeda T; Kita T
    Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H709-15. PubMed ID: 16183734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure.
    Okada H; Takemura G; Kosai K; Li Y; Takahashi T; Esaki M; Yuge K; Miyata S; Maruyama R; Mikami A; Minatoguchi S; Fujiwara T; Fujiwara H
    Circulation; 2005 May; 111(19):2430-7. PubMed ID: 15867170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panax Notoginseng Saponins Inhibits Ventricular Remodeling after Myocardial Infarction in Rats Through Regulating ATF3/MAP2K3/p38 MAPK and NF κ B Pathway.
    Ma RF; Chen G; Li HZ; Zhang Y; Liu YM; He HQ; Liu CY; Xie ZC; Zhang ZP; Wang J
    Chin J Integr Med; 2020 Dec; 26(12):897-904. PubMed ID: 33259022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeic acid mitigates myocardial fibrosis and improves heart function in post-myocardial infarction by inhibiting transforming growth factor-β receptor 1 signaling pathways.
    Jiang W; Deng B; Xie M; Feng Y; Jiang X; Yang B; Tan Z; Ou H; Tan Y; Liu S; Zhang S; Zhang J; Zhou Y; Wu W; Liu B
    Biomed Pharmacother; 2024 Aug; 177():117012. PubMed ID: 38906025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function.
    Szabó Z; Vainio L; Lin R; Swan J; Hulmi JJ; Rahtu-Korpela L; Serpi R; Laitinen M; Pasternack A; Ritvos O; Kerkelä R; Magga J
    FASEB J; 2020 Aug; 34(8):9911-9924. PubMed ID: 32427381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of Myostatin Improves Cardiac Function Following Myocardial Infarction.
    Lim S; McMahon CD; Matthews KG; Devlin GP; Elston MS; Conaglen JV
    Heart Lung Circ; 2018 Jun; 27(6):693-701. PubMed ID: 28690022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qiliqiangxin Attenuates Cardiac Remodeling via Inhibition of TGF-β1/Smad3 and NF-κB Signaling Pathways in a Rat Model of Myocardial Infarction.
    Han A; Lu Y; Zheng Q; Zhang J; Zhao Y; Zhao M; Cui X
    Cell Physiol Biochem; 2018; 45(5):1797-1806. PubMed ID: 29510381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiomyocyte-specific overexpression of oestrogen receptor β improves survival and cardiac function after myocardial infarction in female and male mice.
    Schuster I; Mahmoodzadeh S; Dworatzek E; Jaisser F; Messaoudi S; Morano I; Regitz-Zagrosek V
    Clin Sci (Lond); 2016 Mar; 130(5):365-76. PubMed ID: 26608078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction.
    McCarroll CS; He W; Foote K; Bradley A; Mcglynn K; Vidler F; Nixon C; Nather K; Fattah C; Riddell A; Bowman P; Elliott EB; Bell M; Hawksby C; MacKenzie SM; Morrison LJ; Terry A; Blyth K; Smith GL; McBride MW; Kubin T; Braun T; Nicklin SA; Cameron ER; Loughrey CM
    Circulation; 2018 Jan; 137(1):57-70. PubMed ID: 29030345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide improves myocardial fibrosis after myocardial infarction through inhibition of CTGF by activating cAMP in mice.
    Huang DD; Huang HF; Yang Q; Chen XQ
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4648-4656. PubMed ID: 30058704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ginsenoside Rg2 attenuates myocardial fibrosis and improves cardiac function after myocardial infarction via AKT signaling pathway.
    Li X; Xiang N; Wang Z
    Biosci Biotechnol Biochem; 2020 Nov; 84(11):2199-2206. PubMed ID: 32706304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice.
    Gao S; Li L; Li L; Ni J; Guo R; Mao J; Fan G
    J Mol Cell Cardiol; 2019 Dec; 137():59-70. PubMed ID: 31629735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse.
    LaPointe MC; Mendez M; Leung A; Tao Z; Yang XP
    Am J Physiol Heart Circ Physiol; 2004 Apr; 286(4):H1416-24. PubMed ID: 14670812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Effect of CD137 Deficiency Against Postinfarction Cardiac Fibrosis and Adverse Cardiac Remodeling by ERK1/2 Signaling Pathways.
    Zang G; Chen Y; Guo G; Wan A; Li B; Wang Z
    J Cardiovasc Pharmacol; 2024 May; 83(5):446-456. PubMed ID: 38416872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction.
    Most P; Seifert H; Gao E; Funakoshi H; Völkers M; Heierhorst J; Remppis A; Pleger ST; DeGeorge BR; Eckhart AD; Feldman AM; Koch WJ
    Circulation; 2006 Sep; 114(12):1258-68. PubMed ID: 16952982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.